Methyl salicylate

Identification

Summary

Methyl salicylate is a topical counter-irritant used for the symptomatic relief of acute musculoskeletal pain in the muscles, joints, and tendons.

Brand Names
Dendracin Neurodendraxcin, Flexall Ultra Plus, Lidopro, Listerine Antiseptic, Medi-derm, Medi-derm With Lidocaine, Medrox, Mentholatum, Rematex, Salonpas Pain Relieving Patch, Tiger Balm, Xoten-C
Generic Name
Methyl salicylate
DrugBank Accession Number
DB09543
Background

Methyl salicylate (oil of wintergreen or wintergreen oil) is an organic ester naturally produced by many species of plants, particularly wintergreens. The compound was first extracted and isolated from plant species Gaultheria procumbens in 1843. It can be manufactured synthetically and it used as a fragrance, in foods, beverages, and liniments. It forms a colorless to yellow or reddish liquid and exhibits a characteristic odor and taste of wintergreen. For acute joint and muscular pain, methyl salicylate is used as a rubefacient and analgesic in deep heating liniments. It is used as a flavoring agent in chewing gums and mints in small concentrations and added as antiseptic in mouthwash solutions.

Type
Small Molecule
Groups
Approved, Vet approved
Structure
Weight
Average: 152.1473
Monoisotopic: 152.047344122
Chemical Formula
C8H8O3
Synonyms
  • 2-(Methoxycarbonyl)phenol
  • 2-Carbomethoxyphenol
  • 2-Hydroxybenzoic acid methyl ester
  • Betula oil
  • Gaultheria oil
  • Methyl 2-hydroxybenzoate
  • Methyl o-hydroxybenzoate
  • Methyl salicylate
  • Natural wintergreen oil
  • Oil of wintergreen
  • Spicewood Oil
  • Sweet birch oil
  • Teaberry oil

Pharmacology

Indication

Ointments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbago,sciatica and rheumatic conditions. Local analgesics for human and veterinary medicine.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAcute muscle painCombination Product in combination with: Piroxicam (DB00554), Eugenol (DB09086), Levomenthol (DB00825)••• ••••••
Used in combination for symptomatic treatment ofArthritisCombination Product in combination with: Levomenthol (DB00825), Camphor (DB01744), Eucalyptus oil (DB11114)••• •••••••••••
Used as adjunct in combination to treatBack pain lower backCombination Product in combination with: Levomenthol (DB00825), Chlorobutanol (DB11386), Camphor (DB01744)••• •••••••••••
Used in combination to treatBack pain lower backCombination Product in combination with: Camphor (DB01744), Levomenthol (DB00825), Eucalyptus oil (DB11114)••• ••••••
Used in combination to treatBackacheCombination Product in combination with: Levomenthol (DB00825), Eucalyptus oil (DB11114), Camphor (DB01744)••• •••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Methyl salicylate relieve musculoskeletal pain in the muscles, joints, and tendons by causing irritation and reddening of the skin due to dilated capillaries and increased blood flow. It is pharmacologically similar to aspirin and other NSAIDs but as a topical agent it primarily acts as a rubefacient and skin irritant. Counter-irritation is believed to cause a soothing sensation of warmth.

Mechanism of action

Counter-irritation is thought to be effective at alleviating musculoskeletal pain as the irritation of the sensory nerve endings is thought to alter or offset pain in the underlying muscle or joints that are served by the same nerves 5. This is thought to mask the underlying musculoskeletal pain and discomfort. When applied topically, methyl salicylate is thought to penetrate the skin and underlying tissues where it reversibly inhibits cyclooxygenase enzyme and locally and peripherally prevents the production of inflammatory mediators such as prostaglandin and thromboxane A2.

Absorption

Approximately 12-20% of topically applied methyl salicylate may be systemically absorbed through intact skin within 10 hours of application, and absorption varies with different conditions such as surface area and pH. Dermal bioavailability is in the range of 11.8 – 30.7%. For the assessment of potential oral exposure to salicylates, bioavailability is assumed to be 100% 9.

Volume of distribution

After absorption, methyl salicylate is distributed throughout most body tissues and most transcellular fluids, primarily by pH dependent passive processes. Salicylate is actively transported by a low-capacity, saturable system out of the CSF across the choroid plexus. The drug readily crosses the placental barrier.

Protein binding

Degree of albumin binding depends on the plasma concentration of the compound

Metabolism

Minor metabolism may occur in various tissues but hepatic metabolism constitutes the majority of metabolic processes of absorbed methyl salicylate. It is mainly hydrolyzed to salicylic acid via hepatic esterase enzymes. Conjugation with glycine forms salicyluric acid and conjugation with glucuronic forms ester or acyl and ether or phenolic glucuronide, which are the three main metabolites.

Hover over products below to view reaction partners

Route of elimination

Excreted by kidneys as free salicylic acid (10%), salicyluric acid (75%), salicylic phenolic (10%) and acyl glucuronide (5%), and gentisic acid (less than 1%).

Half-life

The plasma half-life for salicylate is 2 to 3 hr in low doses and about 12 hr at usual anti-inflammatory doses. The half-life of salicylate may be as long as 15 to 30 hr at high therapeutic doses or when there is intoxication.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Oral LD50 values (mg/kg) for mouse, rat and rabbit are 1110, 887 and 1300, respectively. Oral LD50 values for child and adult human (mg/kg) are 228 and 506, respectively. Although systemic toxicity from topical administration is rare, methyl salicylate can be absorbed in intract skin to cause stimulation of the central nervous system respiratory center, disturbance of lipid and carbohydrate metabolism, and disturbance of intracellular respiration. Severe toxicity can result in acute lung injury, lethargy, coma, seizures, cerebral edema, and death. In case of salicylate poisoning, the treatment consists of general supportive care, gastrointestinal decontamination with activated charcoal in cases of salicylate ingestion, and monitoring of serum salicylate concentrations. Bicarbonate infusions or hemodialysis can be used to achieve enhanced salicylate elimination 7.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Abciximab.
AcarboseMethyl salicylate may increase the hypoglycemic activities of Acarbose.
AceclofenacThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Aceclofenac.
AcenocoumarolMethyl salicylate may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Methyl salicylate.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Salicylic acidunknownO414PZ4LPZ69-72-7YGSDEFSMJLZEOE-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Abejas y Viboras Roll OnLiquid10 g/100gTopicalMENPER DISTRIBUTORS INC.2021-03-31Not applicableUS flag
Activ-Rub LinimentLinimentTopicalWINWA MEDICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
ANTIFLAM RUBCreamTopicalPRIME PHARMACEUTICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
ANTIPAIN LINIMENT 25%LinimentTopicalZONTRON PHARMACEUTICALS SDN. BHD.2020-09-08Not applicableMalaysia flag
Aspi-Rub Pain RelieverSpray23 g/100gTopicalAspiRub Enterprises LLC2014-08-29Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
1st Medxpatch With Lidocaine 4%Methyl salicylate (20 g/1) + Capsaicin (0.025 g/1) + Lidocaine (4 g/1) + Menthol (5 g/1)PatchTopical1ST MEDX LLC2018-03-15Not applicableUS flag
365 Whole Foods Market Anticavity/Antigingivitis MouthwashMethyl salicylate (0.6 mg/1mL) + Eucalyptol (0.92 mg/1mL) + Menthol (0.42 mg/1mL) + Sodium fluoride (0.1 mg/1mL) + Thymol (0.64 mg/1mL)MouthwashDentalWhole Foods Market, Inc.2022-01-31Not applicableUS flag
365 Whole Foods Market Antigingivitis MouthwashMethyl salicylate (0.6 mg/1mL) + Eucalyptol (0.92 mg/1mL) + Menthol (0.42 mg/1mL) + Thymol (0.64 mg/1mL)MouthwashDentalWhole Foods Market, Inc.2022-01-31Not applicableUS flag
701 Dieda Zhengtong Yaogao MedicatedMethyl salicylate (10 g/1) + Menthol (8 g/1) + Synthetic camphor (3.1 g/1)PlasterTopical; TransdermalGUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO., LTD. BAIYUNSHAN HEJIGONG PHARMACEUTICAL FACTORY2001-10-15Not applicableUS flag
AA Top MedicatedMethyl salicylate (0.05 g/1mL) + Menthol (0.1 g/1mL)OilTopicalAlbert Max, Inc.2018-02-01Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
1st Medxpatch With Lidocaine 4%-rxMethyl salicylate (20 g/1) + Capsaicin (0.0375 g/1) + Lidocaine (4 g/1) + Menthol (5 g/1)PatchTopical1ST MEDX LLC2018-03-15Not applicableUS flag
1st Medxpatch With Lidocaine 4%-rxMethyl salicylate (20 1/1) + Capsaicin (0.0375 1/1) + Lidocaine (4 1/1) + Menthol (5 1/1)PatchTopicalDirect Rx2020-10-14Not applicableUS flag
AdazinMethyl salicylate (1 g/100g) + Benzocaine (2 g/100g) + Capsaicin (0.035 g/100g) + Lidocaine (2 g/100g)CreamTopicalSterling Knight Pharmaceuticals, Llc2014-12-032018-10-01US flag
AMULDY SPORTS gelMethyl salicylate (0.3 g/100mL) + Camphor (0.05 g/100mL) + Menthol (2.5 g/100mL) + Salicylic acid (0.03 g/100mL)LiquidTopicalLydia Co., Ltd.2020-04-24Not applicableUS flag
Anesthall Pain Relieving CreamMethyl salicylate (6.1 g/100g) + Menthol (4.6 g/100g)CreamTopicalAdvanced Pharmaceutics Inc2023-12-11Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as o-hydroxybenzoic acid esters. These are benzoic acid esters where the benzene ring is ortho-substituted with a hydroxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
o-Hydroxybenzoic acid esters
Alternative Parents
Salicylic acid and derivatives / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Methyl esters / Monocarboxylic acids and derivatives / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Aromatic homomonocyclic compound / Benzoyl / Carboxylic acid derivative / Carboxylic acid ester / Hydrocarbon derivative / Methyl ester / Monocarboxylic acid or derivatives / O-hydroxybenzoic acid ester
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
salicylates, benzoate ester (CHEBI:31832) / a small molecule (CPD-6442)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
LAV5U5022Y
CAS number
119-36-8
InChI Key
OSWPMRLSEDHDFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3
IUPAC Name
methyl 2-hydroxybenzoate
SMILES
COC(=O)C1=CC=CC=C1O

References

General References
  1. He YY, Yan Y, Zhang HF, Lin YH, Chen YC, Yan Y, Wu P, Fang JS, Yang SH, Du GH: Methyl salicylate 2-O-beta-d-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction. Drug Des Devel Ther. 2016 Sep 29;10:3183-3196. eCollection 2016. [Article]
  2. Xin W, Huang C, Zhang X, Xin S, Zhou Y, Ma X, Zhang D, Li Y, Zhou S, Zhang D, Zhang T, Du G: Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice. Br J Pharmacol. 2014 Jul;171(14):3526-38. doi: 10.1111/bph.12715. [Article]
  3. Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ: Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004 Apr 24;328(7446):995. Epub 2004 Mar 19. [Article]
  4. Higashi Y, Kiuchi T, Furuta K: Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther. 2010 Jan;32(1):34-43. doi: 10.1016/j.clinthera.2010.01.016. [Article]
  5. Derry S, Matthews PR, Wiffen PJ, Moore RA: Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2014 Nov 26;(11):CD007403. doi: 10.1002/14651858.CD007403.pub3. [Article]
  6. Moore RA, Derry S, McQuay HJ: Topical analgesics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2010;(7). pii: CD008609. [Article]
  7. Thompson TM, Toerne T, Erickson TB: Salicylate Toxicity from Genital Exposure to a Methylsalicylate-Containing Rubefacient. West J Emerg Med. 2016 Mar;17(2):181-3. doi: 10.5811/westjem.2016.1.29262. Epub 2016 Mar 2. [Article]
  8. FDA SALONPAS® Pain Relief Patch Clinical Review [Link]
  9. Norwegian Food Safety Authority: Methyl salicylate risk review [Link]
Human Metabolome Database
HMDB0034172
KEGG Drug
D01087
KEGG Compound
C12305
PubChem Compound
4133
PubChem Substance
347827876
ChemSpider
13848808
RxNav
29787
ChEBI
31832
ChEMBL
CHEMBL108545
ZINC
ZINC000000000490
Drugs.com
Drugs.com Drug Page
Wikipedia
Methyl_salicylate
MSDS
Download (55.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionHealthy Volunteers (HV)1
4CompletedTreatmentChronic Lower Back Pain (CLBP)2
4CompletedTreatmentSub-acute Back Pain1
3Not Yet RecruitingTreatmentPain1
3RecruitingTreatmentMigraine1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
MouthwashBuccal; Dental
Aerosol, sprayPercutaneous; Topical; Transdermal
Aerosol, sprayCutaneous; Topical; Transdermal
SprayTopical
OintmentEnteral
CreamTopical
LinimentTopical
MouthwashOral
SprayTopical23 g/100g
MouthwashBuccal
OintmentTopical10.5 g/90g
SolutionTopical
OilPercutaneous; Topical; Transdermal
OintmentCutaneous
PowderTopical
SolutionTransdermal3 g/100mL
SprayTopical60 mg/1mL
Oil
LotionTopical10 g/100mL
LotionTopical10 g/1g
MouthwashDental
GelTransdermal
PatchTransdermal
OintmentTopical
PlasterTransdermal
CreamTopical7 g
KitTopical
LinimentTopical
LiquidDental
SalveTopical
SolutionBuccal; Oral
Plaster
LiquidTopical15 g/100g
CrystalTopical
CreamTopical250 mg/1mL
OintmentTopical100 mg/1mL
OintmentTopical20 mg/1mL
PatchCutaneous; Topical; Transdermal
Solution, concentrateOral
PasteTopical
StickTopical.25 g/1g
LinimentTopical25 %
LiquidTopical980 mg/1mL
PlasterTopical1 g/1
OilTopical60 g/100mL
OintmentTopical13.5 g/100g
KitOral; Topical
StickTopical
LiquidRespiratory (inhalation)
LiquidTopical
OintmentTopical10.5 g/100g
OintmentTopical15 g/100g
OintmentTopical12 g/100g
OintmentTopical15 g/113g
OintmentTopical12 g/113g
OilTopical25 g/100mL
RinseOral
OilTopical105 mg/1mL
SolutionTopical25 %v/v
InhalantNasal
CreamTopical250 mg/1g
PatchTopical100 mg/1000mg
PatchTopical10 g/1
OintmentTopical
OintmentTopical10 g/100g
SprayOral
CreamTopical
JellyNasal
GelTopical105 mg/1g
LotionTopical20 g/100g
Capsule; kit; liquidOral; Topical
KitOral
PatchTopical
LiquidOral
LiquidCutaneous
PatchTopical; Transdermal
Kit; patchTopical
PatchPercutaneous; Topical; Transdermal
OilTopical
LiquidTopical40 g/100mL
LotionTopical0.95 %
GelPercutaneous; Topical; Transdermal
SprayCutaneous
Aerosol, foamPercutaneous; Topical; Transdermal
OintmentPercutaneous; Topical; Transdermal
Aerosol, sprayTopical
LiquidCutaneous; Topical; Transdermal
LiquidTopical10 g/100g
PatchTopical10 mg/100mg
PatchTopical10 g/100g
EmulsionTopical10 %
LotionTopical0.95 % w/v
StickTopical10 g/100mL
CreamTopical100 mg/1g
CreamTopical10 g/100g
GelTopical
LotionTopical
EmulsionTopical15 g/100g
OintmentTopical15 mg/100g
OintmentTopical5 mg/100g
CreamCutaneous
AerosolTopical
GelTopical100 mg/1g
OintmentTopical10 g
LinimentTopical25 g/100ml
Cream; kit; solutionTopical
OintmentTopical15.75 g/150g
LiquidTopical12 g/100mL
LiquidTopical12 mg/100mL
LiquidTopical7 g/100mL
OilTransdermal
LiquidTopical
PlasterTopical; Transdermal
CreamTopical10 g/100mL
PlasterTopical
PoulticeTransdermal160 mg/17g
PoulticeTransdermal105 mg/17.5g
LiquidTopical200 mg/1g
SolutionOral
OilTopical100 ml/100ml
OilTopical35 ml/100ml
OilTopical36 ml/100ml
EmulsionTopical5 ml/100ml
CreamTopical14 %w/w
EmulsionTopical
CreamTopical12 %w/w
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US8809615No2014-08-192030-01-03US flag
US9233184No2016-01-122027-08-01US flag

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-8.6MSDS
boiling point (°C)220-224MSDS
water solubilitySlightly solubleMSDS
logP2.5MSDS
Predicted Properties
PropertyValueSource
Water Solubility5.73 mg/mLALOGPS
logP2.07ALOGPS
logP2.32Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)9.72Chemaxon
pKa (Strongest Basic)-4.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area46.53 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity40.06 m3·mol-1Chemaxon
Polarizability14.98 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00di-5900000000-bb69ba7d9fb7889830b6
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9800000000-4c121b87ee97a30f4150
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9800000000-aeff759175e190d33827
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9700000000-8449a003796d4c61d429
Mass Spectrum (Electron Ionization)MSsplash10-00dl-9800000000-1d56d6cf07db519b50e2
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0fk9-3900000000-e2029bf3c75775175ff3
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-2900000000-78821514531802772904
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-fb3f08730fd647d588fe
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dl-8900000000-d6a4791b8a356f623555
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-32709565f41dfd735704
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-1003-9300000000-571b97f20ed9c5e06c16
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0296-9000000000-f1ace40ea88fc9be46e5
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-132.2217102
predicted
DarkChem Lite v0.1.0
[M-H]-131.7101102
predicted
DarkChem Lite v0.1.0
[M-H]-132.2150102
predicted
DarkChem Lite v0.1.0
[M-H]-132.1670102
predicted
DarkChem Lite v0.1.0
[M-H]-129.27269
predicted
DeepCCS 1.0 (2019)
[M+H]+132.7134102
predicted
DarkChem Lite v0.1.0
[M+H]+131.8589102
predicted
DarkChem Lite v0.1.0
[M+H]+133.0046102
predicted
DarkChem Lite v0.1.0
[M+H]+132.7290102
predicted
DarkChem Lite v0.1.0
[M+H]+133.04425
predicted
DeepCCS 1.0 (2019)
[M+Na]+132.4824102
predicted
DarkChem Lite v0.1.0
[M+Na]+131.7454102
predicted
DarkChem Lite v0.1.0
[M+Na]+132.3076102
predicted
DarkChem Lite v0.1.0
[M+Na]+132.3778102
predicted
DarkChem Lite v0.1.0
[M+Na]+142.29716
predicted
DeepCCS 1.0 (2019)

Drug created at November 30, 2015 19:10 / Updated at March 18, 2024 16:48